Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADALIMUMAB Cause Intentional product use issue? 3,557 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,557 reports of Intentional product use issue have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.7% of all adverse event reports for ADALIMUMAB.

3,557
Reports of Intentional product use issue with ADALIMUMAB
0.7%
of all ADALIMUMAB reports
1,333
Deaths
1,841
Hospitalizations

How Dangerous Is Intentional product use issue From ADALIMUMAB?

Of the 3,557 reports, 1,333 (37.5%) resulted in death, 1,841 (51.8%) required hospitalization, and 1,622 (45.6%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 3,557 reports have been filed with the FAERS database.

What Other Side Effects Does ADALIMUMAB Cause?

Drug ineffective (71,926) Pain (37,514) Arthralgia (35,592) Rheumatoid arthritis (29,817) Fatigue (29,420) Injection site pain (28,679) Headache (19,891) Nausea (19,299) Rash (18,690) Pain in extremity (18,319)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280) HYDROXYCHLOROQUINE (3,059)

Which ADALIMUMAB Alternatives Have Lower Intentional product use issue Risk?

ADALIMUMAB vs ADALIMUMAB-AACF ADALIMUMAB vs ADALIMUMAB-AATY ADALIMUMAB vs ADALIMUMAB-ADAZ ADALIMUMAB vs ADALIMUMAB-ADBM ADALIMUMAB vs ADALIMUMAB-AFZB

Related Pages

ADALIMUMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue ADALIMUMAB Demographics